Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

Open access
Scholz, Alexander, Harter, Patrick N, Cremer, Sebastian, Yalcin, Burak H, Gurnik, Stefanie, Yamaji, Maiko, Di Tacchio, Mariangela, Sommer, Kathleen, Baumgarten, Peter, Bähr, Oliver, Steinbach, Joachim P, Trojan, Jörg, Glas, Martin, Herrlinger, Ulrich, Krex, Dietmar, Meinhardt, Matthias, Weyerbrock, Astrid, Timmer, Marco, Goldbrunner, Roland, Deckert, Martina, Braun, Christian, Schittenhelm, Jens, Frueh, Jochen T, Ullrich, Evelyn, Mittelbronn, Michel, Plate, Karl H, Reiss, Yvonne·2016·EMBO Molecular Medicine

Abstract

Glioblastoma multiforme (GBM) is treated by surgical resection followed by radiochemotherapy. Bevacizumab is commonly deployed for anti-angiogenic therapy of recurrent GBM; however, innate immune cells have been identified as instigators of resistance to bevacizumab treatment. We identified angiopoietin-2 (Ang-2) as a potential target in both naive and bevacizumab-treated glioblastoma. Ang-2 expression was absent in normal human brain endothelium, while the highest Ang-2 levels were observed in bevacizumab-treated GBM. In a murine GBM model, VEGF blockade resulted in endothelial upregulation of Ang-2, whereas the combined inhibition of VEGF and Ang-2 leads to extended survival, decreased vascular permeability, depletion of tumor-associated macrophages, improved pericyte coverage, and increased numbers of intratumoral T lymphocytes. CD206(+) (M2-like) macrophages were identified as potential novel targets following anti-angiogenic therapy. Our findings imply a novel role for endothelial cells in therapy resistance and identify endothelial cell/myeloid cell crosstalk mediated by Ang-2 as a potential resistance mechanism. Therefore, combining VEGF blockade with inhibition of Ang-2 may potentially overcome resistance to bevacizumab therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201505505

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 169

Metadata

Authors
Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bähr, O., Steinbach, J. P., Trojan, J., Glas, M., Herrlinger, U., Krex, D., Meinhardt, M., Weyerbrock, A., Timmer, M., Goldbrunner, R., Deckert, M., Braun, C., Schittenhelm, J., Frueh, J. T., Ullrich, E., Mittelbronn, M., Plate, K. H., & Reiss, Y.
Venue
EMBO Molecular Medicine
Published
2015-12-14
Volume
8
Issue
1
Pages
39-57
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2261205543
Cited by
169
References
18
FWCI
6.05
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma. https://app.cochat.ai/papers/10.15252/emmm.201505505
The paper
Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bähr, O., Steinbach, J. P., Trojan, J., Glas, M., Herrlinger, U., Krex, D., Meinhardt, M., Weyerbrock, A., Timmer, M., Goldbrunner, R., . . . Reiss, Y. (2016). Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201505505

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.